Abstract
Inhaled corticosteroids (ICS) are the cornerstone of asthma management both in adults and in children. There are some adverse effects related to the use of these drugs in all ages. Those adverse effects can be local or systemic. From the paediatric point of view, the main worry relates to the effect on growth and on the integrity of the HPA-axis. At the recommended doses, their effect on the latter is not clinically relevant and the slight modification of cortisol levels which occurs while taking them reflects their presence in blood. Although there is a slowing down on growth velocity, this is reduced to the first months of treatment which are followed by a catch up: there is quite consistent data supporting their lack of significant effect on the final height. Other adverse effects which may appear in relation to ICS treatment in children, including infants, are mild or very sporadic. However, it is important to bear in mind that a small proportion of asthmatic children may have a certain idiosyncrasy which makes them especially sensitive to ICS. Furthermore, a close follow up is warranted when, due to the disease severity, higher than the recommended doses of ICS are administered.
Keywords: Adverse effects, asthma, inhaled corticosteroids, safety
Current Drug Safety
Title: Inhaled Corticosteroids in Asthmatic Children: Are They as Safe in Infants and Preschoolers as in Older Children? A Review
Volume: 3 Issue: 1
Author(s): Luis Garcia-Marcos, Jose A. Ros-Lucas and Manuel Sanchez-Solis
Affiliation:
Keywords: Adverse effects, asthma, inhaled corticosteroids, safety
Abstract: Inhaled corticosteroids (ICS) are the cornerstone of asthma management both in adults and in children. There are some adverse effects related to the use of these drugs in all ages. Those adverse effects can be local or systemic. From the paediatric point of view, the main worry relates to the effect on growth and on the integrity of the HPA-axis. At the recommended doses, their effect on the latter is not clinically relevant and the slight modification of cortisol levels which occurs while taking them reflects their presence in blood. Although there is a slowing down on growth velocity, this is reduced to the first months of treatment which are followed by a catch up: there is quite consistent data supporting their lack of significant effect on the final height. Other adverse effects which may appear in relation to ICS treatment in children, including infants, are mild or very sporadic. However, it is important to bear in mind that a small proportion of asthmatic children may have a certain idiosyncrasy which makes them especially sensitive to ICS. Furthermore, a close follow up is warranted when, due to the disease severity, higher than the recommended doses of ICS are administered.
Export Options
About this article
Cite this article as:
Garcia-Marcos Luis, Ros-Lucas A. Jose and Sanchez-Solis Manuel, Inhaled Corticosteroids in Asthmatic Children: Are They as Safe in Infants and Preschoolers as in Older Children? A Review, Current Drug Safety 2008; 3 (1) . https://dx.doi.org/10.2174/157488608783334005
DOI https://dx.doi.org/10.2174/157488608783334005 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Chemogenomics with Peptide Secondary Structure Mimetics
Combinatorial Chemistry & High Throughput Screening Practical Review of Mechanical Ventilation in Adults and Children in the Operating Room and Emergency Department
Reviews on Recent Clinical Trials Inhaled Corticosteroids in COPD: Pros and Cons
Current Drug Targets Role of CHRNA5-A3 Genetic Locus Variants and Developing Drug for Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry Gastrin-Releasing Peptide as a Molecular Target for Inflammatory Diseases: An Update
Inflammation & Allergy - Drug Targets (Discontinued) Dendritic Nanoparticles for Cutaneous Drug Delivery - Testing in Human Skin and Reconstructed Human Skin
Current Pharmaceutical Design Anti-Viral
Current Bioactive Compounds Mast Cells in Abdominal Aortic Aneurysms
Current Vascular Pharmacology Development and Clinical use of Prasugrel and Ticagrelor
Current Pharmaceutical Design Medical Management and Risk Reduction of the Cardiovascular Effects of Underwater Diving
Current Vascular Pharmacology SAR and Molecular Modeling of N-Benzyl-N-hydroxy-3-(cyclopentyloxy)-4- methoxybenzene Carboxamide Analogues as Potent Phosphodiesterase-4 Inhibitors
Letters in Drug Design & Discovery Proteomic Insights into Inflammatory Airway Diseases
Current Proteomics Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Time-Effect of Formoterol Added to Inhaled Fluticasone on Exercise- Induced Bronchoconstriction in Asthmatic Adolescents
Current Respiratory Medicine Reviews The Role of CTLA-4 Gene Polymorphisms in Autoimmune Disease Pathogenesis: A 2012 Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Epidemiology of NHP-Drug Interactions: Identification and Evaluation
Current Drug Metabolism Mass Spectrometric Analysis of F2-Isoprostanes: Markers and Mediators in Human Disease
Current Pharmaceutical Analysis Inflammatory Cellular Phenotypes and Molecular Mechanisms of Glucocorticoid Resistance in Patients with Bronchial Asthma
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Structure-Based Rationale for Interleukin 5 Receptor Antagonism
Current Pharmaceutical Design